Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
PHASE3
110 participants
INTERVENTIONAL
2025-08-31
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Phase 1b Trial to Evaluate the Safety of MB310 in Patients With Active, Mild-to-Moderate Ulcerative Colitis
NCT06582264
A Study to Evaluate the Safety, Tolerability and Microbiome Dynamics of SER-287 in Subjects With Mild-to-Moderate Ulcerative Colitis
NCT02618187
Study of Bio-K+® in the Reduction of the Risk of Clostridium Difficile Infection and Antibiotic Associated Diarrhea
NCT01972932
Safety, Blood Levels and Effects of MGB-BP-3
NCT02518607
Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease
NCT00350298
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Experimental
PBK\_M2502, 1-Day Regimen
PBK_M2502 1-Day
Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
active Comparator
PBK\_M2502, 2-Day Regimen
PBK_M2502 2-Day
Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
PBK_M2502 1-Day
Subjects who are randomized into group test 2 will receive bowel preparation on the same-day.
PBK_M2502 2-Day
Subjects who are randomized into group test 1 will receive bowel preparation from evening to next morning.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients who is scheduled a esophagogastroduodenoscopy and colonoscopy
* BMI 19≤and\<30
Exclusion Criteria
* Pregnant or breast-feeding women who do not want to stop breast-feeding
* Uncontrolled hypertension
* Uncontrolled diabetes
* Fluid or electrolyte (Na, K, Ca, Mg, chloride, bicarbonate) disturbance
* HIV infection and/or chronic hepatitis B or C
* Patients who has a difficulty to participate because of severe nausea or vomiting
* History of colon surgery and abdominal surgery within 6 month; need an emergency surgery
19 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pharmbio Korea Co., Ltd.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kyung Hee University Hospital at Gangdong
Seoul, Gangdong-gu, South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PBK_M2502_301
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.